Home / fusion test / Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.


Sorafenib, a novel drug for metastatic renal cancer, has broad-spectrum activity against multiple tyrosine kinases, including Raf-1, vascular endothelial growth factor receptor and platelet-derived growth factor receptor.

However, little is known about its effects on the immune system.

In this report, we examine the effects of sorafenib on the proliferation and activation of human peripheral blood T cells, as well as its effects on T-cell-mediated immune response in mice.

At concentrations similar to those used in patients, sorafenib inhibited the proliferation of primary human T cells in vitro.

At more than 10 microM, sorafenib caused an irrecoverable inhibition of proliferation, even after drug withdrawal.

In addition, sorafenib induced T-cell apoptosis at concentrations higher than 10 muM.

G(0)/G(1) phase arrest, inhibition of CD25 and CD69 expression, interleukin-2 production and LCK phosphorylation in the T cells; all of these effects exhibited dose and time dependence.

When tested against contact dermatitis in mice, sorafenib significantly reduced the ear swelling induced by picryl chloride.

These findings suggest that sorafenib may cause the loss of T-cell immune response by inducing apoptosis and targeting LCK.

This could potentially lead to immunosuppression in patients with cancer.

Full Article


Check Also

sodium thiosulfate (Rx)

medscape-emedicine Dosing & Uses AdultPediatric Dosage Forms & Strengths injection solution 100mg/mL (10%) 250mg/mL (25%) Cyanide Poisoning 12. IV (infuse over 10-20 minutes) Cisplatin Extravasation 2 mL 1/6 molar solution through IV cannula for every 100 mg cisplatin; remove needle, then inject 0. L injections clockwise around extravasation area up to 1 mL; repeat several …

Leave a Reply

Your email address will not be published. Required fields are marked *